These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 35491266)
1. Quality by Design for enabling RNA platform production processes. Daniel S; Kis Z; Kontoravdi C; Shah N Trends Biotechnol; 2022 Oct; 40(10):1213-1228. PubMed ID: 35491266 [TBL] [Abstract][Full Text] [Related]
2. Accelerating attribute-focused process and product development through the development and deployment of autonomous process analytical technology platform system. Wu CR; Chan B; Sarich Z; Duan Y; Chen J; Song JL; Berke M; Miranda LP; Goudar CT Biotechnol Bioeng; 2024 Apr; 121(4):1257-1270. PubMed ID: 38328831 [TBL] [Abstract][Full Text] [Related]
3. Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality. Nunavath RS; Singh MT; Jain A; Chakma M; Arivuselvam R; Azeeze MSTA Drug Res (Stuttg); 2024 Jan; 74(1):18-23. PubMed ID: 38134919 [TBL] [Abstract][Full Text] [Related]
4. Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. van de Berg D; Kis Z; Behmer CF; Samnuan K; Blakney AK; Kontoravdi C; Shattock R; Shah N NPJ Vaccines; 2021 Apr; 6(1):65. PubMed ID: 33927197 [TBL] [Abstract][Full Text] [Related]
5. Is it advantageous to use quality by design (QbD) to develop nanoparticle-based dosage forms for parenteral drug administration? Camacho Vieira C; Peltonen L; Karttunen AP; Ribeiro AJ Int J Pharm; 2024 May; 657():124163. PubMed ID: 38670473 [TBL] [Abstract][Full Text] [Related]
6. Advances and opportunities in process analytical technologies for viral vector manufacturing. Sripada SA; Hosseini M; Ramesh S; Wang J; Ritola K; Menegatti S; Daniele MA Biotechnol Adv; 2024 Sep; 74():108391. PubMed ID: 38848795 [TBL] [Abstract][Full Text] [Related]
7. Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends. Biscaia-Caleiras M; Fonseca NA; Lourenço AS; Moreira JN; Simões S J Control Release; 2024 Jul; 373():617-639. PubMed ID: 39002799 [TBL] [Abstract][Full Text] [Related]
8. Integrated Process Modeling-A Process Validation Life Cycle Companion. Zahel T; Hauer S; Mueller EM; Murphy P; Abad S; Vasilieva E; Maurer D; Brocard C; Reinisch D; Sagmeister P; Herwig C Bioengineering (Basel); 2017 Oct; 4(4):. PubMed ID: 29039771 [TBL] [Abstract][Full Text] [Related]
9. Understanding the impact of Lenk R; Kleindienst W; Szabó GT; Baiersdörfer M; Boros G; Keller JM; Mahiny AJ; Vlatkovic I Front Mol Biosci; 2024; 11():1426129. PubMed ID: 39050733 [TBL] [Abstract][Full Text] [Related]
10. Quality by Digital Design for Developing Platform RNA Vaccine and Therapeutic Manufacturing Processes. Nair A; Loveday KA; Kenyon C; Qu J; Kis Z Methods Mol Biol; 2024; 2786():339-364. PubMed ID: 38814403 [TBL] [Abstract][Full Text] [Related]
15. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282 [TBL] [Abstract][Full Text] [Related]
16. Breaking the mold with RNA-a "RNAissance" of life science. Jones CH; Androsavich JR; So N; Jenkins MP; MacCormack D; Prigodich A; Welch V; True JM; Dolsten M NPJ Genom Med; 2024 Jan; 9(1):2. PubMed ID: 38195675 [TBL] [Abstract][Full Text] [Related]
17. Amplifying mRNA vaccines: potential versatile magicians for oncotherapy. Hu C; Liu J; Cheng F; Bai Y; Mao Q; Xu M; Liang Z Front Immunol; 2023; 14():1261243. PubMed ID: 37936701 [TBL] [Abstract][Full Text] [Related]
18. Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery. Gurba-Bryśkiewicz L; Maruszak W; Smuga DA; Dubiel K; Wieczorek M Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893125 [TBL] [Abstract][Full Text] [Related]